Research ArticleInfectious Disease

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

See allHide authors and affiliations

Science Translational Medicine  03 May 2017:
Vol. 9, Issue 388, eaaj1928
DOI: 10.1126/scitranslmed.aaj1928

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

No eLetters have been published for this article.

Stay Connected to Science Translational Medicine